HC Wainwright Issues Negative Estimate for PRAX Earnings

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Stock analysts at HC Wainwright dropped their Q1 2025 earnings estimates for shares of Praxis Precision Medicines in a research report issued on Monday, March 3rd. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($3.18) per share for the quarter, down from their previous forecast of ($2.96). HC Wainwright currently has a “Buy” rating and a $105.00 target price on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($10.22) per share. HC Wainwright also issued estimates for Praxis Precision Medicines’ Q2 2025 earnings at ($3.64) EPS, Q3 2025 earnings at ($4.15) EPS, Q4 2025 earnings at ($4.16) EPS, FY2025 earnings at ($15.13) EPS, Q1 2026 earnings at ($4.39) EPS, Q2 2026 earnings at ($4.82) EPS, Q3 2026 earnings at ($4.89) EPS, Q4 2026 earnings at ($4.90) EPS, FY2026 earnings at ($18.99) EPS, FY2027 earnings at ($15.64) EPS, FY2028 earnings at ($15.64) EPS and FY2029 earnings at $23.38 EPS.

Several other research firms have also commented on PRAX. Needham & Company LLC reduced their price target on shares of Praxis Precision Medicines from $150.00 to $85.00 and set a “buy” rating for the company in a research report on Monday. Wedbush lowered shares of Praxis Precision Medicines from a “hold” rating to a “strong sell” rating in a report on Friday, February 28th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Praxis Precision Medicines in a report on Tuesday, February 11th. They issued a “buy” rating and a $111.00 target price for the company. Truist Financial reduced their target price on shares of Praxis Precision Medicines from $175.00 to $85.00 and set a “buy” rating for the company in a report on Monday. Finally, Robert W. Baird reduced their target price on shares of Praxis Precision Medicines from $117.00 to $73.00 and set an “outperform” rating for the company in a report on Monday. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Praxis Precision Medicines has a consensus rating of “Moderate Buy” and a consensus price target of $123.80.

Praxis Precision Medicines Stock Up 0.1 %

NASDAQ PRAX opened at $37.87 on Wednesday. Praxis Precision Medicines has a 52 week low of $30.01 and a 52 week high of $91.83. The firm has a market capitalization of $763.57 million, a P/E ratio of -3.68 and a beta of 2.76. The company has a 50-day moving average price of $72.93 and a 200-day moving average price of $69.09.

Praxis Precision Medicines (NASDAQ:PRAX) last released its quarterly earnings results on Friday, February 28th. The company reported ($2.94) EPS for the quarter, missing the consensus estimate of ($2.76) by ($0.18). Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%. The business had revenue of $7.48 million for the quarter, compared to analysts’ expectations of $0.36 million.

Institutional Investors Weigh In On Praxis Precision Medicines

A number of institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its holdings in Praxis Precision Medicines by 7.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,208,522 shares of the company’s stock valued at $93,008,000 after buying an additional 88,442 shares in the last quarter. Vanguard Group Inc. grew its holdings in Praxis Precision Medicines by 2.4% during the 4th quarter. Vanguard Group Inc. now owns 1,063,639 shares of the company’s stock valued at $81,858,000 after buying an additional 24,645 shares in the last quarter. VR Adviser LLC grew its holdings in Praxis Precision Medicines by 40.2% during the 4th quarter. VR Adviser LLC now owns 989,985 shares of the company’s stock valued at $76,189,000 after buying an additional 283,854 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Praxis Precision Medicines by 77.5% during the 4th quarter. Janus Henderson Group PLC now owns 929,523 shares of the company’s stock valued at $71,621,000 after acquiring an additional 405,957 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Praxis Precision Medicines by 5,437.7% during the 4th quarter. Assenagon Asset Management S.A. now owns 559,082 shares of the company’s stock valued at $43,027,000 after acquiring an additional 548,986 shares during the last quarter. 67.84% of the stock is owned by hedge funds and other institutional investors.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.